Last reviewed · How we verify
UC-MSCs and Secretomes
At a glance
| Generic name | UC-MSCs and Secretomes |
|---|---|
| Sponsor | PT. Prodia Stem Cell Indonesia |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis (PHASE1, PHASE2)
- Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct (PHASE1, PHASE2)
- Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance. (PHASE1, PHASE2)
- Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis (PHASE1, PHASE2)
- The Placental Secretome as a Therapeutic Tool to Prevent Inflammation-induced Preterm Birth (NA)
- Skin Rejuvenation Using Stem Cell Secretome (PHASE1)
- Effectiveness of PRP, Conditioned Medium UC-MSCs Secretome and Hyaluronic Acid for the Treatment of Knee Osteoarthritis (PHASE1, PHASE2)
- Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UC-MSCs and Secretomes CI brief — competitive landscape report
- UC-MSCs and Secretomes updates RSS · CI watch RSS
- PT. Prodia Stem Cell Indonesia portfolio CI